A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Giredestrant|DRUG: Triptorelin|DRUG: Anastrozole
Sponsor: ETOP IBCSG Partners Foundation
Collaborators: Hoffmann-La Roche